
News|Articles|February 13, 2019
Ultomiris for Paroxysmal Nocturnal Hemoglobinuria
Author(s)Drew Boxler
Advertisement
ULTOMIRIS (ravulizumab-cwvz , Alexion Pharmaceuticals, Inc.)
Indications: treatment of adult patients with paroxysmal nocturnal hemoglobinuria
Dosage: intravenous infusion only
- 40 kg ≤ X< 60 kg – 2,400mg leading, 3,000 mg maintenance
- 60kg ≤ X < 100kg – 2,700mg leading, 3,300mg maintenance
- 100kg ≤ X – 3,000mg leading, 3,600 maintenance
Contraindications: patients with unresolved Neisseria Meningitidis infection.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Q&A: Why Community Pharmacies are Displeased with the MDPNP | NCPA 2025
2
COVID-19 Vaccination Benefits Patients With Systemic Lupus Erythematosus
3
Pharmacies Should Prioritize Medicare Transaction Facilitator Enrollment | NCPA 2025
4
General Awareness of PBM Practices Driving Optimism for Independent Pharmacies | NCPA 2025
5




















































































































































